Aqilion’s Board of Directors consists of professionals with a mix of solid and broad experience to ensure the company’s long-term development and strategic management of the projects.

Johan Lund
Johan Lund
Chairman since 2018
Read more
Johan Lund
Johan Lund
Chairman since 2018

MD, PhD. Dr Johan Lund is an experienced scientific leader of drug discovery and development. He is the CEO and co-founder of KyNexis Medicine Development AB and founder of MBS Pharma. Most recently, he was Vice President of Translational R&D, at Celgene, Cambridge, MA, USA, where he was responsible for discovery and early development of new therapies for diseases within Inflammation and Immunology. Prior positions include Chief Scientific Officer, Immunoscience Research Unit at Pfizer, Cambridge, MA, and 14 years with AstraZeneca in senior positions in both Sweden and the UK, VP CNS & Pain Innovative Medicines Science and VP Respiratory and Inflammation Research. Presently, he is also member of the board of Olink Proteomics, Genagon Therapeutics, TCER AB, KyNexis Medicine Development AB and MBS Pharma AB.

Jörgen Johnsson
Jörgen Johnsson
Vice Chairman since 2011
Read more
Jörgen Johnsson
Jörgen Johnsson
Vice Chairman since 2011

Studies in business administration and marketing corresponding to an MBA. During the years 1979-2000, he held several international and leading positions in Swedish pharmaceutical companies and he actively participated in the development and transformation of the industry throughout the 1980s and 1990s. After Pharmacia’s acquisition of Upjohn Company, Pharmacia Corporation was formed. He was then CEO of the Group’s Consumer Drugs Division, Consumer Healthcare Worldwide. He was also Senior Vice President of Pharmacia Corporation and a member of the Group’s operational management team until he chose to leave the industry for other interests in 2000. He is the founder of AQILION AB and innovator in multiple Aqilion project companies.

Roland Andersson
Roland Andersson
Board member since 2018
Read more
Roland Andersson
Roland Andersson
Board member since 2018

MD, PhD, Professor of surgery, Faculty of Medicine, Lund University, Sweden. Professor Roland Andersson’s clinical practice and research focuses on malignancies of the pancreas, liver and biliary tract. He leads a translational research group focused on the development of new biomarker panels for diagnostics, forecasting, prediction, choice of therapy and outcomes, as well as the disease itself. He has published about 500 original articles, reviewed articles and book chapters, and has been a supervisor for 30 PhD students. He has an extensive international network and, as an entrepreneur, has founded six companies. Currently he is the chairman of Reccan Diagnostics AB and Nordic Biotechnology AB as well as board member of Lumito AB. He also sits on the Scientific Advisory Board of Volition Rx Ltd.

Marie Lidgard
Marie Lidgard
Board member since 2014
Read more
Marie Lidgard
Marie Lidgard
Board member since 2014

LL.M, Senior Partner Lavindia AB, a lawyer by training with extensive experience in the financial services industry. Marie Lidgard’s background includes Managing Director of the Swedish Investment Fund Association and Senior Vice President of Nordea Investment Management. She has also been involved with recruitment and worked for the Swedish Ministry of Industry, where she was responsible for recruiting board members to state-owned companies. In recent years, she has been active as an investor and founder of several new enterprises. Currently she is the chairman of Dreams Securities AB and Fundrella AB as well as board member of Von Euler och Partners Kapitalförvaltning AB, Hypoteket Fondförvaltning AB, Film Capital Stockholm AB, MoM Lidgard AB and Lavindia AB.

Martin Olovsson
Martin Olovsson
Board member since 2019
Read more
Martin Olovsson
Martin Olovsson
Board member since 2019

B.Sc., Business Administration. Martin Olovsson is an experienced leader with broad experience from portfolio & product strategy, life cycle management, bridging science & market and commercial excellence among others. Currently CEO of AstraZeneca’s spin-out company OnDosis developing and commercializing a connected handheld dosing device platform for oral medicines. From 1992-2017 he has held several international senior positions within Astra/AstraZeneca, for example, President of the Nordic/Baltic marketing- and sales company and Vice President Inhaled Respiratory franchise, Global Portfolio & Product Strategy. He is also board member of WntResearch AB and Scientific Med AB.

Andreas Segerros
Andreas Segerros
Board member since 2018
Read more
Andreas Segerros
Andreas Segerros
Board member since 2018

M.Sc., MBA. Andreas Segerros has spent most of his career in the global pharma, in executive positions (R&D, Marketing and Business Development) in the US, Europe and Japan, at Pharmacia Corporation, Pharmacia & Upjohn and Ferring. His venture capital experience comes from being Venture Partner och Partner at Sunstone Capital. He has made numerous investments in successful life science growth companies. Currently, he is the chairman of Oncorena AB and Oncorena Holding AB as well as board member of Eir Ventures Partners AB and Merigen AB.

Karin Wingstrand
Karin Wingstrand
Board member since 2013
Read more
Karin Wingstrand
Karin Wingstrand
Board member since 2013

M.Sc. Pharmacy. Karin Wingstrand has extensive senior experience of pharmaceutical research and development from roles such as Global Head and Vice President Clinical Development at AstraZeneca, as well as Global Head and Vice President Pharmaceutical and Analytical R&D, AstraZeneca. She is also board member of Mevia AB, T-bolaget AB, Xbrane Biopharma AB, Histolab Products AB and Integrum AB.